Ozempic and Wegovy Lawsuits

2026 Update

In 2026, the litigation involving GLP‑1 medications (primarily Ozempic and Wegovy) is advancing on multiple fronts, with federal lawsuits alleging gastroparesis and other severe gastrointestinal injuries consolidated in a Multidistrict Litigation (MDL 3094) in the Eastern District of Pennsylvania and a separate, newer MDL (3163) as well as a New Jersey Multicounty Litigation (MCL) addressing claims of sudden vision loss from NAION (non‑arteritic anterior ischemic optic neuropathy). As the science has matured, the litigation continues to focus more closely on the two primary types of alleged injuries: 1) gastroparesis; and 2) NAION. Gastroparesis, sometimes described as stomach paralysis, is a condition where the stomach empties much more slowly than it should, causing persistent nausea, vomiting, bloating, abdominal pain, and an inability to tolerate normal meals; in more serious cases it can lead to malnutrition, repeated hospitalizations, and the need for feeding tubes. Currently, the Courts overseeing the litigation now generally require an objective test such as a gastric emptying study to confirm the diagnosis of gastroparesis. NAION is a serious eye condition that affects the optic nerve and can cause sudden, often permanent vision loss in one or both eyes. Recent medical studies have reported a higher‑than‑expected rate of NAION in patients taking semaglutide medications compared with other treatments, prompting regulators in Europe to recognize NAION as a rare but important risk for this class of medications. Feel free to contact our trial lawyers at Stark & Stark to discuss the complex and evolving GLP‑1 landscape and claims.

Key takeaways:

• A major federal court ruling now requires plaintiffs alleging stomach paralysis to have a diagnosis confirmed by specific medical testing, like a gastric emptying study.
• A significant and growing number of lawsuits now focus on severe vision injuries, including irreversible blindness, which are being pursued in both federal and New Jersey state courts.
• While some claims against the drug manufacturers were dismissed, the court allowed core allegations of misleading marketing and failure to warn about gastroparesis to proceed.
• New medical studies continue to emerge, suggesting potential links between these drugs and other serious conditions, including retinal vein occlusion and macular degeneration.
• The litigation is advancing on two main fronts: gastroparesis claims centralized in a Philadelphia federal court and vision injury claims gaining momentum in New Jersey.

A Critical Ruling Reshapes Gastroparesis Lawsuits

A recent order from the federal judge overseeing the national Ozempic multidistrict litigation (MDL) has established a new standard for stomach paralysis claims. This decision directly impacts who may qualify to move forward with a lawsuit.

The Gastric Emptying Study Requirement

The court ruled that any plaintiff claiming to suffer from gastroparesis must have a diagnosis confirmed by objective medical evidence. This means a doctor’s clinical impression alone is not enough. 

The diagnosis must be based on a properly performed gastric emptying study or a similar validated test. This ruling clarifies the evidence required for these specific claims. It sets a clear standard that attorneys must meet when filing a gastroparesis case on behalf of a client.

• A confirmed diagnosis via a gastric emptying study (scintigraphy).
• Diagnosis confirmed through a wireless motility capsule (WMC).
• Diagnosis supported by a gastric emptying breath test.

While this requirement may exclude some individuals who did not receive this specific testing, it strengthens the cases for those who have this definitive proof. It provides a solid, scientific foundation for claims moving forward in the litigation.

What Claims Did the Court Allow to Proceed?

The drug manufacturers asked the court to dismiss many of the claims against them. Judge Karen Spencer Marston’s ruling was a mixed result. She dismissed claims related to design defects but allowed the central allegations to survive. This means the fight for accountability continues on key issues of corporate responsibility.

The court rejected the defense’s argument that their marketing was mere “puffery.” It found that plaintiffs had sufficiently identified specific safety claims that could have misled patients. Most importantly, claims that the manufacturers failed to warn about gastroparesis on the drug’s label will proceed.

The Emerging Front: Severe Vision Injury Lawsuits

While gastroparesis initially defined the litigation, a second and equally serious category of injuries has come into focus: permanent vision loss. These cases are now generating significant attention from both the legal and medical communities.

The Rise of NAION Claims in New Jersey

A growing number of plaintiffs are filing lawsuits in New Jersey state court alleging that Ozempic and Wegovy caused an irreversible condition called non-arteritic anterior ischemic optic neuropathy (NAION). 

This condition involves a sudden loss of blood flow to the optic nerve, causing permanent blindness.

Over 30 plaintiffs have petitioned to consolidate these cases into a multicounty litigation (MCL) in New Jersey. Similar to a federal MDL, this process streamlines pretrial proceedings for efficiency and consistency.

New Medical Research Raises More Concerns

The legal claims are being bolstered by emerging scientific research. A recent study in JAMA Ophthalmology found a potential link between these drugs and other serious eye conditions. These findings add to the body of evidence suggesting the vascular effects of these medications might have unintended consequences. Which is why many turn to a defective drugs & medical devices lawyer for guidance and accountability.

A Two-Front Battle: Federal MDL and State Courts

The legal strategy for holding manufacturers accountable is now advancing in two distinct arenas. This dual approach allows attorneys to pursue justice for different types of injuries in the venues best suited for those claims.

The Gastroparesis MDL in Philadelphia

The federal MDL in Philadelphia remains the central hub for all stomach paralysis cases filed in federal courts across the country. With over 2,000 cases, this litigation will focus on what the companies knew about gastroparesis risks.

New Jersey’s Focus on Vision Injuries

The push to create a separate, coordinated proceeding in New Jersey for NAION claims highlights the unique scientific evidence tied to vision loss. Pursuing these cases in state court may offer a different path to trial, potentially avoiding procedural hurdles that can slow down federal MDLs.

What These Updates Mean for Patients

These recent developments provide both clarity and direction. For those with confirmed gastroparesis, the path forward in the federal MDL is more defined. For those who have suffered vision loss, the growing focus in New Jersey state courts offers a promising new avenue for accountability. The legal system is actively working through these complex scientific and factual issues.

FAQ for Ozempic and Wegovy Lawsuits

What is the difference between the federal MDL and the New Jersey MCL?

The federal MDL, located in Philadelphia, consolidates all federal lawsuits alleging gastroparesis. The proposed New Jersey MCL would consolidate state-level lawsuits specifically alleging vision loss injuries like NAION. They are separate proceedings focused on different primary injuries.

Do I need to have a gastric emptying study before I can contact an attorney?

No. If you have been diagnosed with gastroparesis or are suffering from its severe symptoms after taking Ozempic or Wegovy, you can still seek a legal consultation. An attorney can review your medical history and help you understand if additional testing might be necessary for your claim.

What is NAION and how is it related to these drugs?

NAION is a sudden and permanent vision loss caused by a lack of blood flow to the optic nerve. Lawsuits allege that the vascular effects of drugs like Ozempic may contribute to or cause this condition, and that the manufacturer failed to warn of this risk.

Is it too late for me to consider filing a lawsuit?

Every state has a time limit for filing a personal injury claim, known as a statute of limitations. Because information about these severe side effects is still emerging, it is important to act quickly to protect your rights. Consulting with an attorney can help you determine the deadline for your situation.

Let Us Review Your Case

The personal injury attorneys at Stark & Stark closely monitor all developments in the Ozempic and Wegovy lawsuits in both federal and state courts. If you or a family member suffered from severe gastroparesis or vision loss after using these medications in New Jersey or Pennsylvania, we are here to help. 

Call us at 800.535.3425 for a free, confidential case evaluation.